Cargando…

Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer

Detalles Bibliográficos
Autores principales:	Kandalaft, Lana E, Chiang, Cheryl, Zsiros, Emese, Tanyi, Janos, Powell, Daniel, Mick, Rosemarie, Coukos, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991071/ http://dx.doi.org/10.1186/2051-1426-1-S1-P220

Ejemplares similares

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
por: Kandalaft, Lana E., et al.
Publicado: (2013)

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2012)

Whole Tumor Antigen Vaccines: Where Are We?
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2015)

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer
por: Tanyi, Janos L., et al.
Publicado: (2021)

Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer
por: Tanyi, Janos L., et al.
Publicado: (2021)

Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2011)

Clinical translation section: accelerating the pace from bench to bedside
por: Kandalaft, Lana E, et al.
Publicado: (2011)

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate
por: Chiang, Cheryl L-L, et al.
Publicado: (2011)

Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2021)

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study
por: Ghezelayagh, Talayeh S., et al.
Publicado: (2023)

A chimeric antigen receptor against prostate-specific membrane antigen, a tumor vasculature target
por: Santoro, Stephen P, et al.
Publicado: (2013)

Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens
por: Prickett, Todd D, et al.
Publicado: (2015)

TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer
por: Matthaiou, Efthymia-Iliana, et al.
Publicado: (2022)

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
por: Barber, Emma L., et al.
Publicado: (2013)

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes
por: Svane, I, et al.
Publicado: (2014)

BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control
por: McGray, A J Robert, et al.
Publicado: (2023)

Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes
por: Orcurto, Angela, et al.
Publicado: (2020)

Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity
por: Bassani-Sternberg, Michal, et al.
Publicado: (2017)

Individual cultures of melanoma tumor infiltrating lymphocytes possess distinct patterns of reactivity with mutated antigens identified by whole exome sequencing of autologous tumors
por: Crystal, Jessica S, et al.
Publicado: (2014)

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
por: Sarivalasis, Apostolos, et al.
Publicado: (2019)

Sensitive and frequent identification of high avidity neo-epitope specific CD8(+) T cells in immunotherapy-naive ovarian cancer
por: Bobisse, Sara, et al.
Publicado: (2018)

Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
por: Martin Lluesma, Silvia, et al.
Publicado: (2018)

Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors
por: Yakkala, Chakradhar, et al.
Publicado: (2019)

Enrichment and expansion with nanoscale artificial antigen presenting cells for T cell adoptive immunotherapy
por: Perica, Karlo, et al.
Publicado: (2014)

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
por: Bassani-Sternberg, Michal, et al.
Publicado: (2019)

Cancer Vaccines in Ovarian Cancer: How Can We Improve?
por: Martin Lluesma, Silvia, et al.
Publicado: (2016)

Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival
por: Karapetsas, Athanasios, et al.
Publicado: (2015)

Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes
por: Adams, Sarah F, et al.
Publicado: (2020)

Whole‐exome sequencing of ovarian cancer families uncovers putative predisposition genes
por: Zhu, Qianqian, et al.
Publicado: (2019)

Benign lesions that mimic cancer: Ovarian
por: Forstner, Rosemarie, et al.
Publicado: (2015)

Whole-body diffusion-weighted MRI versus CT for detection, restaging and operability assessment of recurrent ovarian carcinoma
por: Michielsen, K, et al.
Publicado: (2014)

Cancer immunotherapy with multiple tumor antigen activated autologous T cells in patients with HBV related hepatocellular carcinoma
por: Han, Yanyan, et al.
Publicado: (2014)

Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells
por: Benencia, Fabian, et al.
Publicado: (2008)

Naive CD8+ T cells from ART respond to primary vaccination against autologous HIV-1 antigen
por: Smith, Kellie N, et al.
Publicado: (2012)

Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity
por: Fritah, Hajer, et al.
Publicado: (2023)

Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges
por: Iyer, Rohin K., et al.
Publicado: (2018)

Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer
por: Starbuck, Kristen D., et al.
Publicado: (2018)

Study of autologous dendritic cell therapy targeting Mucin 1 as a treatment for the maintenance of ovarian cancer patients in remission
por: Goh, J, et al.
Publicado: (2013)

Believe in yourself, and enjoy the ride
por: Kandalaft, Lana E.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_60v3csvuou17fm7vhu7ddjvqis